Achim's practice covers a wide range of chemical, pharmaceutical and high tech inventions, and he is acting for a diverse range of companies across these technologies, from start-ups to multinationals.
Achim regularly advises clients on the IP aspects of complex technologies, and on the creation and management of cost-effective IP portfolios.
He also regularly represents clients in Opposition and Appeal Proceedings before the European Patent Office, and often supports clients in multi-jurisdictional contentious situations.
Another field involves due diligence investigations into IP portfolios of technology companies, primarily for venture capital and private equity investors.
Achim is presently serving as President of the LES Benelux.
Achim is qualified as a Dutch, Belgian and European Patent Attorney, and he is a registered European Trade Mark and Design Attorney.
Dr. Rer. Nat.
CEIPI Patent Litigation
"Achim Krebs appreciates what clients really need and gives made-to-measure advice. He is strategic and has a strong commercial understanding of intellectual property and how it can be used to serve business purposes.” He protects chemical, pharmaceutical and mechanical inventions from his base at HGF in The Hague.
October 12th 2020
November 4th 2019
April 21st 2016
September 6th 2013
March 22nd 2012
President of the Licensing Executive Society for the Benelux for 2020/2021. Secretary LES Benelux 2008-2018.
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF is sponsoring WIPR Trademarks Live conference 2021 with Partner Lee Curtis speaking on 8th June. WIPR Trademarks Live is designed to provide critical and timely insights from leading trademark …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.